Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 290 entries
Sorted by: Best Match Show Resources per page
[Societies of all kinds].

Le Chirurgien-dentiste de France

Faye JC.
PMID: 1073280
Chir Dent Fr. 1975 Nov 05;45(277):55-6 contd..

No abstract available.

Cite
Faye JC. Des sociétés en tous genres. [Societies of all kinds]. Chir Dent Fr. 1975;45(277):55-6 contd.
Faye, J. C. (1975). Des sociétés en tous genres. [Societies of all kinds]. Le Chirurgien-dentiste de France, 45(277), 55-6 contd..
Faye, J C. "Des sociétés en tous genres." [Societies of all kinds]. Le Chirurgien-dentiste de France vol. 45,277 (1975): 55-6 contd..
Faye JC. Des sociétés en tous genres. [Societies of all kinds]. Chir Dent Fr. 1975 Nov 05;45(277):55-6 contd.. French. PMID: 1073280.
Copy Download .nbib Format: NLM
Corrigendum: Pervasive computing technologies to continuously assess Alzheimer's disease progression and intervention efficacy.

Frontiers in aging neuroscience

Lyons BE, Austin D, Seelye A, Petersen J, Yeargers J, Riley T, Sharma N, Mattek N, Dodge H, Wild K, Kaye JA.
PMID: 26696884
Front Aging Neurosci. 2015 Dec 11;7:232. doi: 10.3389/fnagi.2015.00232. eCollection 2015.

[This corrects the article on p. 102 in vol. 7, PMID: 26113819.].

Cite
Lyons BE, Austin D, Seelye A, et al. Corrigendum: Pervasive computing technologies to continuously assess Alzheimer's disease progression and intervention efficacy. Front Aging Neurosci. 2015;7:232doi: 10.3389/fnagi.2015.00232.
Lyons, B. E., Austin, D., Seelye, A., Petersen, J., Yeargers, J., Riley, T., Sharma, N., Mattek, N., Dodge, H., Wild, K., & Kaye, J. A. (2015). Corrigendum: Pervasive computing technologies to continuously assess Alzheimer's disease progression and intervention efficacy. Frontiers in aging neuroscience, 7232. https://doi.org/10.3389/fnagi.2015.00232
Lyons, Bayard E, et al. "Corrigendum: Pervasive computing technologies to continuously assess Alzheimer's disease progression and intervention efficacy." Frontiers in aging neuroscience vol. 7 (2015): 232. doi: https://doi.org/10.3389/fnagi.2015.00232
Lyons BE, Austin D, Seelye A, Petersen J, Yeargers J, Riley T, Sharma N, Mattek N, Dodge H, Wild K, Kaye JA. Corrigendum: Pervasive computing technologies to continuously assess Alzheimer's disease progression and intervention efficacy. Front Aging Neurosci. 2015 Dec 11;7:232. doi: 10.3389/fnagi.2015.00232. eCollection 2015. PMID: 26696884; PMCID: PMC4675995.
Copy Download .nbib Format: NLM
Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib.

Advances in hematology

Davis KL, Côté I, Kaye JA, Mendelson E, Gao H, Perez Ronco J.
PMID: 26635878
Adv Hematol. 2015;2015:848473. doi: 10.1155/2015/848473. Epub 2015 Nov 09.

Few trial-based assessments of ruxolitinib in patients with lower-risk myelofibrosis (MF) have been conducted, and no studies have made such assessments in a real-world population. We assessed changes in spleen size and constitutional symptoms during ruxolitinib treatment using a...

Cite
Davis KL, Côté I, Kaye JA, et al. Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib. Adv Hematol. 2015;2015:848473doi: 10.1155/2015/848473.
Davis, K. L., Côté, I., Kaye, J. A., Mendelson, E., Gao, H., & Perez Ronco, J. (2015). Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib. Advances in hematology, 2015848473. https://doi.org/10.1155/2015/848473
Davis, Keith L, et al. "Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib." Advances in hematology vol. 2015 (2015): 848473. doi: https://doi.org/10.1155/2015/848473
Davis KL, Côté I, Kaye JA, Mendelson E, Gao H, Perez Ronco J. Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib. Adv Hematol. 2015;2015:848473. doi: 10.1155/2015/848473. Epub 2015 Nov 09. PMID: 26635878; PMCID: PMC4655278.
Copy Download .nbib Format: NLM
Correction to: NuA4 histone acetyltransferase activity is required for H4 acetylation on a dosage-compensated monosomic chromosome that confers resistance to fungal toxins.

Epigenetics & chromatin

Wakabayashi H, Tucker C, Bethlendy G, Kravets A, Welle SL, Bulger M, Hayes JJ, Rustchenko E.
PMID: 29115969
Epigenetics Chromatin. 2017 Nov 07;10(1):52. doi: 10.1186/s13072-017-0161-1.

After the publication of this work [1], it was noticed that an initial was missing from the author name: Jeffrey Hayes. His name should be written as: Jeffrey J. Hayes.

Cite
Wakabayashi H, Tucker C, Bethlendy G, et al. Correction to: NuA4 histone acetyltransferase activity is required for H4 acetylation on a dosage-compensated monosomic chromosome that confers resistance to fungal toxins. Epigenetics Chromatin. 2017;10(1):52doi: 10.1186/s13072-017-0161-1.
Wakabayashi, H., Tucker, C., Bethlendy, G., Kravets, A., Welle, S. L., Bulger, M., Hayes, J. J., & Rustchenko, E. (2017). Correction to: NuA4 histone acetyltransferase activity is required for H4 acetylation on a dosage-compensated monosomic chromosome that confers resistance to fungal toxins. Epigenetics & chromatin, 10(1), 52. https://doi.org/10.1186/s13072-017-0161-1
Wakabayashi, Hironao, et al. "Correction to: NuA4 histone acetyltransferase activity is required for H4 acetylation on a dosage-compensated monosomic chromosome that confers resistance to fungal toxins." Epigenetics & chromatin vol. 10,1 (2017): 52. doi: https://doi.org/10.1186/s13072-017-0161-1
Wakabayashi H, Tucker C, Bethlendy G, Kravets A, Welle SL, Bulger M, Hayes JJ, Rustchenko E. Correction to: NuA4 histone acetyltransferase activity is required for H4 acetylation on a dosage-compensated monosomic chromosome that confers resistance to fungal toxins. Epigenetics Chromatin. 2017 Nov 07;10(1):52. doi: 10.1186/s13072-017-0161-1. PMID: 29115969; PMCID: PMC5674758.
Copy Download .nbib Format: NLM
The effects of noncoding aquaporin-4 single-nucleotide polymorphisms on cognition and functional progression of Alzheimer's disease.

Alzheimer's & dementia (New York, N. Y.)

Burfeind KG, Murchison CF, Westaway SK, Simon MJ, Erten-Lyons D, Kaye JA, Quinn JF, Iliff JJ.
PMID: 29067342
Alzheimers Dement (N Y). 2017 May 26;3(3):348-359. doi: 10.1016/j.trci.2017.05.001. eCollection 2017 Sep.

INTRODUCTION: The glymphatic system is a brain-wide perivascular network that facilitates clearance of proteins, including amyloid β, from the brain interstitium through the perivascular exchange of cerebrospinal fluid and interstitial fluid. The astrocytic water channel aquaporin-4 (AQP4) is required...

Cite
Burfeind KG, Murchison CF, Westaway SK, et al. The effects of noncoding aquaporin-4 single-nucleotide polymorphisms on cognition and functional progression of Alzheimer's disease. Alzheimers Dement (N Y). 2017;3(3):348-359doi: 10.1016/j.trci.2017.05.001.
Burfeind, K. G., Murchison, C. F., Westaway, S. K., Simon, M. J., Erten-Lyons, D., Kaye, J. A., Quinn, J. F., & Iliff, J. J. (2017). The effects of noncoding aquaporin-4 single-nucleotide polymorphisms on cognition and functional progression of Alzheimer's disease. Alzheimer's & dementia (New York, N. Y.), 3(3), 348-359. https://doi.org/10.1016/j.trci.2017.05.001
Burfeind, Kevin G, et al. "The effects of noncoding aquaporin-4 single-nucleotide polymorphisms on cognition and functional progression of Alzheimer's disease." Alzheimer's & dementia (New York, N. Y.) vol. 3,3 (2017): 348-359. doi: https://doi.org/10.1016/j.trci.2017.05.001
Burfeind KG, Murchison CF, Westaway SK, Simon MJ, Erten-Lyons D, Kaye JA, Quinn JF, Iliff JJ. The effects of noncoding aquaporin-4 single-nucleotide polymorphisms on cognition and functional progression of Alzheimer's disease. Alzheimers Dement (N Y). 2017 May 26;3(3):348-359. doi: 10.1016/j.trci.2017.05.001. eCollection 2017 Sep. PMID: 29067342; PMCID: PMC5651426.
Copy Download .nbib Format: NLM
Treatment Patterns, Costs, and Survival among Medicare-Enrolled Elderly Patients Diagnosed with Advanced Stage Gastric Cancer: Analysis of a Linked Population-Based Cancer Registry and Administrative Claims Database.

Journal of gastric cancer

Karve S, Lorenzo M, Liepa AM, Hess LM, Kaye JA, Calingaert B.
PMID: 26161282
J Gastric Cancer. 2015 Jun;15(2):87-104. doi: 10.5230/jgc.2015.15.2.87. Epub 2015 Jun 30.

PURPOSE: To assess real-world treatment patterns, health care utilization, costs, and survival among Medicare enrollees with locally advanced/unresectable or metastatic gastric cancer receiving standard first-line chemotherapy.MATERIALS AND METHODS: This was a retrospective analysis of the Surveillance, Epidemiology, and End...

Cite
Karve S, Lorenzo M, Liepa AM, et al. Treatment Patterns, Costs, and Survival among Medicare-Enrolled Elderly Patients Diagnosed with Advanced Stage Gastric Cancer: Analysis of a Linked Population-Based Cancer Registry and Administrative Claims Database. J Gastric Cancer. 2015;15(2):87-104doi: 10.5230/jgc.2015.15.2.87.
Karve, S., Lorenzo, M., Liepa, A. M., Hess, L. M., Kaye, J. A., & Calingaert, B. (2015). Treatment Patterns, Costs, and Survival among Medicare-Enrolled Elderly Patients Diagnosed with Advanced Stage Gastric Cancer: Analysis of a Linked Population-Based Cancer Registry and Administrative Claims Database. Journal of gastric cancer, 15(2), 87-104. https://doi.org/10.5230/jgc.2015.15.2.87
Karve, Sudeep, et al. "Treatment Patterns, Costs, and Survival among Medicare-Enrolled Elderly Patients Diagnosed with Advanced Stage Gastric Cancer: Analysis of a Linked Population-Based Cancer Registry and Administrative Claims Database." Journal of gastric cancer vol. 15,2 (2015): 87-104. doi: https://doi.org/10.5230/jgc.2015.15.2.87
Karve S, Lorenzo M, Liepa AM, Hess LM, Kaye JA, Calingaert B. Treatment Patterns, Costs, and Survival among Medicare-Enrolled Elderly Patients Diagnosed with Advanced Stage Gastric Cancer: Analysis of a Linked Population-Based Cancer Registry and Administrative Claims Database. J Gastric Cancer. 2015 Jun;15(2):87-104. doi: 10.5230/jgc.2015.15.2.87. Epub 2015 Jun 30. PMID: 26161282; PMCID: PMC4496446.
Copy Download .nbib Format: NLM
Assessing Treatment-Resistant Posttraumatic Stress Disorder: The Emory Treatment Resistance Interview for PTSD (E-TRIP).

Behavioral sciences (Basel, Switzerland)

Dunlop BW, Kaye JL, Youngner C, Rothbaum B.
PMID: 25494488
Behav Sci (Basel). 2014 Dec 08;4(4):511-527. doi: 10.3390/bs4040511.

Patients with posttraumatic stress disorder (PTSD) who fail to respond to established treatments are at risk for chronic disability and distress. Although treatment-resistant PTSD (TR-PTSD) is a common clinical problem, there is currently no standard method for evaluating previous...

Cite
Dunlop BW, Kaye JL, Youngner C, et al. Assessing Treatment-Resistant Posttraumatic Stress Disorder: The Emory Treatment Resistance Interview for PTSD (E-TRIP). Behav Sci (Basel). 2014;4(4):511-527doi: 10.3390/bs4040511.
Dunlop, B. W., Kaye, J. L., Youngner, C., & Rothbaum, B. (2014). Assessing Treatment-Resistant Posttraumatic Stress Disorder: The Emory Treatment Resistance Interview for PTSD (E-TRIP). Behavioral sciences (Basel, Switzerland), 4(4), 511-527. https://doi.org/10.3390/bs4040511
Dunlop, Boadie W, et al. "Assessing Treatment-Resistant Posttraumatic Stress Disorder: The Emory Treatment Resistance Interview for PTSD (E-TRIP)." Behavioral sciences (Basel, Switzerland) vol. 4,4 (2014): 511-527. doi: https://doi.org/10.3390/bs4040511
Dunlop BW, Kaye JL, Youngner C, Rothbaum B. Assessing Treatment-Resistant Posttraumatic Stress Disorder: The Emory Treatment Resistance Interview for PTSD (E-TRIP). Behav Sci (Basel). 2014 Dec 08;4(4):511-527. doi: 10.3390/bs4040511. PMID: 25494488; PMCID: PMC4287702.
Copy Download .nbib Format: NLM
The emerging need for family-centric initiatives for obtaining consent in personal genome research.

Genome medicine

Minari J, Teare H, Mitchell C, Kaye J, Kato K.
PMID: 25593596
Genome Med. 2014 Dec 17;6(12):118. doi: 10.1186/s13073-014-0118-y. eCollection 2014.

The use of information and communication technology can offer a novel way to promote family-centric initiatives for informed consent, and can address associated ethical challenges in personal genome research.

Cite
Minari J, Teare H, Mitchell C, et al. The emerging need for family-centric initiatives for obtaining consent in personal genome research. Genome Med. 2014;6(12):118doi: 10.1186/s13073-014-0118-y.
Minari, J., Teare, H., Mitchell, C., Kaye, J., & Kato, K. (2014). The emerging need for family-centric initiatives for obtaining consent in personal genome research. Genome medicine, 6(12), 118. https://doi.org/10.1186/s13073-014-0118-y
Minari, Jusaku, et al. "The emerging need for family-centric initiatives for obtaining consent in personal genome research." Genome medicine vol. 6,12 (2014): 118. doi: https://doi.org/10.1186/s13073-014-0118-y
Minari J, Teare H, Mitchell C, Kaye J, Kato K. The emerging need for family-centric initiatives for obtaining consent in personal genome research. Genome Med. 2014 Dec 17;6(12):118. doi: 10.1186/s13073-014-0118-y. eCollection 2014. PMID: 25593596; PMCID: PMC4295276.
Copy Download .nbib Format: NLM
Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.

Neurology

Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, Mohs RC, Thal LJ, Whitehouse PJ, DeKosky ST, Cummings JL.
PMID: 11342679
Neurology. 2001 May 08;56(9):1154-66. doi: 10.1212/wnl.56.9.1154.

OBJECTIVE: To define and investigate key issues in the management of dementia and to make literature-based treatment recommendations.METHODS: The authors searched the literature for four clinical questions: 1) Does pharmacotherapy for cognitive symptoms improve outcomes in patients with dementia?...

Cite
Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1154-66doi: 10.1212/wnl.56.9.1154.
Doody, R. S., Stevens, J. C., Beck, C., Dubinsky, R. M., Kaye, J. A., Gwyther, L., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., & Cummings, J. L. (2001). Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 56(9), 1154-66. https://doi.org/10.1212/wnl.56.9.1154
Doody, R S, et al. "Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology." Neurology vol. 56,9 (2001): 1154-66. doi: https://doi.org/10.1212/wnl.56.9.1154
Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, Mohs RC, Thal LJ, Whitehouse PJ, DeKosky ST, Cummings JL. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001 May 08;56(9):1154-66. doi: 10.1212/wnl.56.9.1154. PMID: 11342679.
Copy Download .nbib Format: NLM
Selenium species: uptake, transformation and toxicities in differing substrates and their pharmaceutical applications.

Metal-based drugs

Kaye KJ.
PMID: 18476238
Met Based Drugs. 1994;1(2):265-77. doi: 10.1155/MBD.1994.265.

No abstract available.

Cite
Kaye KJ. Selenium species: uptake, transformation and toxicities in differing substrates and their pharmaceutical applications. Met Based Drugs. 1994;1(2):265-77doi: 10.1155/MBD.1994.265.
Kaye, K. J. (1994). Selenium species: uptake, transformation and toxicities in differing substrates and their pharmaceutical applications. Metal-based drugs, 1(2), 265-77. https://doi.org/10.1155/MBD.1994.265
Kaye, K J. "Selenium species: uptake, transformation and toxicities in differing substrates and their pharmaceutical applications." Metal-based drugs vol. 1,2 (1994): 265-77. doi: https://doi.org/10.1155/MBD.1994.265
Kaye KJ. Selenium species: uptake, transformation and toxicities in differing substrates and their pharmaceutical applications. Met Based Drugs. 1994;1(2):265-77. doi: 10.1155/MBD.1994.265. PMID: 18476238; PMCID: PMC2364896.
Copy Download .nbib Format: NLM
Radionuclide composition of the allende meteorite from nondestructive gamma-ray spectrometric analysis.

Science (New York, N.Y.)

Rancitelli LA, Perkins RW, Cooper JA, Kaye JH, Wogman NA.
PMID: 17759948
Science. 1969 Dec 05;166(3910):1269-72. doi: 10.1126/science.166.3910.1269.

The concentrations of beryllium-7, sodium-22, aluminum-26, potassium-40, scandium-46, vanadium-48, chromium-51, manganese-54, cobalt-57, cobalt-60, and thorium-232 (thallium-208) have been measured in the Allende meteorite by nondestructive gamma-ray spectrometry. The high cobalt-60 content of the meteorite is indicative of a preatmospheric...

Cite
Rancitelli LA, Perkins RW, Cooper JA, et al. Radionuclide composition of the allende meteorite from nondestructive gamma-ray spectrometric analysis. Science. 1969;166(3910):1269-72doi: 10.1126/science.166.3910.1269.
Rancitelli, L. A., Perkins, R. W., Cooper, J. A., Kaye, J. H., & Wogman, N. A. (1969). Radionuclide composition of the allende meteorite from nondestructive gamma-ray spectrometric analysis. Science (New York, N.Y.), 166(3910), 1269-72. https://doi.org/10.1126/science.166.3910.1269
Rancitelli, L A, et al. "Radionuclide composition of the allende meteorite from nondestructive gamma-ray spectrometric analysis." Science (New York, N.Y.) vol. 166,3910 (1969): 1269-72. doi: https://doi.org/10.1126/science.166.3910.1269
Rancitelli LA, Perkins RW, Cooper JA, Kaye JH, Wogman NA. Radionuclide composition of the allende meteorite from nondestructive gamma-ray spectrometric analysis. Science. 1969 Dec 05;166(3910):1269-72. doi: 10.1126/science.166.3910.1269. PMID: 17759948.
Copy Download .nbib Format: NLM
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium.

Alzheimer's & dementia : the journal of the Alzheimer's Association

Khachaturian ZS, Petersen RC, Gauthier S, Buckholtz N, Corey-Bloom JP, Evans B, Fillit H, Foster N, Greenberg B, Grundman M, Sano M, Simpkins J, Schneider LS, Weiner MW, Galasko D, Hyman B, Kuller L, Schenk D, Snyder S, Thomas RG, Tuszynski MH, Vellas B, Wurtman RJ, Snyder PJ, Frank RA, Albert M, Doody R, Ferris S, Kaye J, Koo E, Morrison-Bogorad M, Reisberg B, Salmon DP, Gilman S, Mohs R, Aisen PS, Breitner JC, Cummings JL, Kawas C, Phelps C, Poirier J, Sabbagh M, Touchon J, Khachaturian AS, Bain LJ.
PMID: 18631960
Alzheimers Dement. 2008 May;4(3):156-63. doi: 10.1016/j.jalz.2008.03.005.

No abstract available.

Cite
Khachaturian ZS, Petersen RC, Gauthier S, et al. A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement. 2008;4(3):156-63doi: 10.1016/j.jalz.2008.03.005.
Khachaturian, Z. S., Petersen, R. C., Gauthier, S., Buckholtz, N., Corey-Bloom, J. P., Evans, B., Fillit, H., Foster, N., Greenberg, B., Grundman, M., Sano, M., Simpkins, J., Schneider, L. S., Weiner, M. W., Galasko, D., Hyman, B., Kuller, L., Schenk, D., Snyder, S., Thomas, R. G., Tuszynski, M. H., Vellas, B., Wurtman, R. J., Snyder, P. J., Frank, R. A., Albert, M., Doody, R., Ferris, S., Kaye, J., Koo, E., Morrison-Bogorad, M., Reisberg, B., Salmon, D. P., Gilman, S., Mohs, R., Aisen, P. S., Breitner, J. C., Cummings, J. L., Kawas, C., Phelps, C., Poirier, J., Sabbagh, M., Touchon, J., Khachaturian, A. S., & Bain, L. J. (2008). A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimer's & dementia : the journal of the Alzheimer's Association, 4(3), 156-63. https://doi.org/10.1016/j.jalz.2008.03.005
Khachaturian, Zaven S, et al. "A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium." Alzheimer's & dementia : the journal of the Alzheimer's Association vol. 4,3 (2008): 156-63. doi: https://doi.org/10.1016/j.jalz.2008.03.005
Khachaturian ZS, Petersen RC, Gauthier S, Buckholtz N, Corey-Bloom JP, Evans B, Fillit H, Foster N, Greenberg B, Grundman M, Sano M, Simpkins J, Schneider LS, Weiner MW, Galasko D, Hyman B, Kuller L, Schenk D, Snyder S, Thomas RG, Tuszynski MH, Vellas B, Wurtman RJ, Snyder PJ, Frank RA, Albert M, Doody R, Ferris S, Kaye J, Koo E, Morrison-Bogorad M, Reisberg B, Salmon DP, Gilman S, Mohs R, Aisen PS, Breitner JC, Cummings JL, Kawas C, Phelps C, Poirier J, Sabbagh M, Touchon J, Khachaturian AS, Bain LJ. A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement. 2008 May;4(3):156-63. doi: 10.1016/j.jalz.2008.03.005. PMID: 18631960; PMCID: PMC2544623.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 290 entries